Clinical Uses of Nalidixic Acid Analogues: the Fluoroquinolones

Overview

Journal Eur J Clin Microbiol

Specialty Microbiology

Date 1986 Apr 1

PMID 3013628

Citations 6

Authors

N Hoiby

Affiliations

Soon will be listed here.

Citing Articles

Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process.

Rabbaa L, Dautrey S, Colas-Linhart N, Carbon C, Farinotti R Antimicrob Agents Chemother. 1996; 40(9):2126-30.

PMID: 8878593 PMC: 163485. DOI: 10.1128/AAC.40.9.2126.

Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Monk J, Price A, Benfield P, Todd P, Ward A Drugs. 1988; 35(4):373-447.

PMID: 3292209 DOI: 10.2165/00003495-198835040-00003.

Decreased sensitivity of Neisseria gonorrhoeae to quinolone compounds.

Wagenvoort J, van der Willigen A, van Noort J Eur J Clin Microbiol. 1986; 5(6):685.

PMID: 3100294 DOI: 10.1007/BF02013305.

Fluoroquinolone antimicrobial agents.

Wolfson J, Hooper D Clin Microbiol Rev. 1989; 2(4):378-424.

PMID: 2680058 PMC: 358131. DOI: 10.1128/CMR.2.4.378.

Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Gonzalez J, Henwood J Drugs. 1989; 37(5):628-68.

PMID: 2663414 DOI: 10.2165/00003495-198937050-00003.

References

Roberts C, Batten J, Hodson M . Ciprofloxacin-resistant Pseudomonas. Lancet. 1985; 1(8443):1442. DOI: 10.1016/s0140-6736(85)91862-8. View

Barry A, Jones R . Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. Antimicrob Agents Chemother. 1984; 25(6):775-7. PMC: 185641. DOI: 10.1128/AAC.25.6.775. View

Crumplin G, Kenwright M, Hirst T . Investigations into the mechanism of action of the antibacterial agent norfloxacin. J Antimicrob Chemother. 1984; 13 Suppl B:9-23. DOI: 10.1093/jac/13.suppl_b.9. View

Miller M, Ghoneim A, Littlewood J . Use of enoxacin in a patient with cystic fibrosis. Lancet. 1985; 1(8429):646. DOI: 10.1016/s0140-6736(85)92192-0. View

Notowicz A, Stolz E, van Klingeren B . A double blind study comparing two dosages of enoxacin for the treatment of uncomplicated urogenital gonorrhoea. J Antimicrob Chemother. 1984; 14 Suppl C:91-4. DOI: 10.1093/jac/14.suppl_c.91. View

Crider S, Colby S, Miller L, HARRISON W, Kerbs S, Berg S . Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin. N Engl J Med. 1984; 311(3):137-40. DOI: 10.1056/NEJM198407193110301. View

Haase D, Harding G, Thomson M, Kennedy J, Urias B, Ronald A . Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora. Antimicrob Agents Chemother. 1984; 26(4):481-4. PMC: 179948. DOI: 10.1128/AAC.26.4.481. View

Rozenberg-Arska M, Dekker A, Verhoef J . Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J Infect Dis. 1985; 152(1):104-7. DOI: 10.1093/infdis/152.1.104. View

Leigh D, Smith E, Marriner J . Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients. J Antimicrob Chemother. 1984; 13 Suppl B:79-83. DOI: 10.1093/jac/13.suppl_b.79. View

10.

Wolfson J, Hooper D . The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985; 28(4):581-6. PMC: 180310. DOI: 10.1128/AAC.28.4.581. View

11.

Sabbaj J, Hoagland V, Shih W . Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother. 1985; 27(3):297-301. PMC: 176264. DOI: 10.1128/AAC.27.3.297. View

12.

Weisser J, Wiedemann B . Elimination of plasmids by new 4-quinolones. Antimicrob Agents Chemother. 1985; 28(5):700-2. PMC: 176363. DOI: 10.1128/AAC.28.5.700. View

13.

Hooper D, Wolfson J . The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985; 28(5):716-21. PMC: 176369. DOI: 10.1128/AAC.28.5.716. View

14.

Bailey R, Peddie B . Enoxacin for the treatment of urinary tract infection. N Z Med J. 1985; 98(777):286-8. View

15.

Haller I . Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains. Antimicrob Agents Chemother. 1985; 28(5):663-6. PMC: 176353. DOI: 10.1128/AAC.28.5.663. View

16.

Chalkley L, Koornhof H . Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother. 1985; 28(2):331-42. PMC: 180242. DOI: 10.1128/AAC.28.2.331. View

17.

Giamarellou H, Daphnis E, Dendrinos C, Daikos G . Experience with ciprofloxacin in the treatment of various infections caused mainly by Pseudomonas aeruginosa. Drugs Exp Clin Res. 1985; 11(5):351-6. View

18.

Reeves D, Lacey R, Mummery R, Mahendra M, Bint A, Newsom S . Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study. J Antimicrob Chemother. 1984; 13 Suppl B:99-105. DOI: 10.1093/jac/13.suppl_b.99. View

19.

Crook S, Selkon J, McLardy Smith P . Clinical resistance to long-term oral ciprofloxacin. Lancet. 1985; 1(8440):1275. DOI: 10.1016/s0140-6736(85)92343-8. View

20.

Benbrook D, Miller R . Effects of norfloxacin on DNA metabolism in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1986; 29(1):1-6. PMC: 180353. DOI: 10.1128/AAC.29.1.1. View